Aarti Drugs Limited
Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2024-25/110
December 24, 2024

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
"Exchange Plaza", Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Ref: Receipt of US FDA EIR for manufacturing facility of the Company

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is further to the intimation given by the Company dated September 20, 2024 and September 25, 2024 on inspection at API manufacturing facility of our Company at Plot No-E-22, MIDC, Tarapur, Maharashtra by United States Food and Drug Administration (US FDA).

We bring to your notice that the Company is in receipt of the Establishment Inspection Report (EIR) from USFDA concluding the inspection as Closed .

The information as per Para A of Part A of Schedule III under Regulation 30 of the Listing Regulations is given below:

Name of the Authority	United States Food and Drug Administration (US FDA)
Nature and details of the action(s) taken, initiated or order(s) passed	United States Food and Drug Administration (US FDA) had conducted an inspection at API manufacturing facility of the Company at Plot No. E-22, MIDC, Tarapur, Maharashtra. Now the Company is in receipt of the Establishment Inspection Report (EIR). EIR is a report which includes details of audit done. FDA has determined that the inspection classification of this facility is "voluntary action indicated" (VAI). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP).

Aarti Drugs Limited
Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	December 20, 2024
Details of the violation(s) / contravention(s) committed or alleged to be committed	There is no violation(s) / contravention(s) committed or alleged to be committed
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There are no financial or material impacts as on date. Company is in receipt of the Establishment Inspection Report (EIR) from US FDA concluding the inspection as closed under 21 CFR 20.64(d)(3). Due to this Company can export the products such as Ciprofloxacin HCl API, Zolpidem Tartrate API, Raloxifene HCl API, Celecoxib API and Niacin API in US Market

You are requested to take this reply on records.

Thanking you,

Yours faithfully,
FOR AARTI DRUGS LIMITED

RUSHIKESH
VIVEK DEOLE

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: F12932